Last but not least, provided that KRAS and PIK3CA mutations are not mutually exclusive, the constitutive activation at physiological concentration of growth factors of both the MAPK and PI3K/AKT pathways would be a selective advantage [108] for cell survival and cancer progression that would be considered when targeting these pathways. The gene discussed is AKT1; the disease is cancer.